KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EBIT: 2011-2024

Historic EBIT for Sarepta Therapeutics (SRPT) over the last 14 years, with Dec 2024 value amounting to $218.1 million.

  • Sarepta Therapeutics' EBIT fell 42751.07% to -$300.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$117.2 million, marking a year-over-year decrease of 408.55%. This contributed to the annual value of $218.1 million for FY2024, which is 181.43% up from last year.
  • According to the latest figures from FY2024, Sarepta Therapeutics' EBIT is $218.1 million, which was up 181.43% from -$267.8 million recorded in FY2023.
  • In the past 5 years, Sarepta Therapeutics' EBIT ranged from a high of $218.1 million in FY2024 and a low of -$564.2 million during FY2020.
  • In the last 3 years, Sarepta Therapeutics' EBIT had a median value of -$267.8 million in 2023 and averaged -$195.3 million.
  • Its EBIT has fluctuated over the past 5 years, first decreased by 16.64% in 2022, then spiked by 181.43% in 2024.
  • Sarepta Therapeutics' EBIT (Yearly) stood at -$564.2 million in 2020, then grew by 18.51% to -$459.7 million in 2021, then declined by 16.64% to -$536.2 million in 2022, then soared by 50.05% to -$267.8 million in 2023, then spiked by 181.43% to $218.1 million in 2024.